Ratchada Cressey
Overview
Explore the profile of Ratchada Cressey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
136
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang L, Guo X, Sun X, Liao J, Liu Q, Ye Y, et al.
Front Immunol
. 2025 Mar;
16:1486329.
PMID: 40040705
Objective: Given the limitations of immunotherapy for treating non-small cell lung cancer (NSCLC), we investigated the phenotype and function of exhausted CD8T cells and analyzed a novel combination immunotherapy to...
2.
Cressey T, Salvadori N, Rabie H, du Toit S, Than-In-At K, Groenewald M, et al.
J Acquir Immune Defic Syndr
. 2025 Feb;
PMID: 39972540
Background: Dolutegravir dispersible tablets (DTG-DT) are approved for infants ≥4 weeks and ≥3 kg but their suitability for neonates remains unknown. Methods: PETITE-DTG is a Phase I/II, open-label, single center,...
3.
Cressey R, Han M, Khaodee W, Xiyuan G, Qing Y
Front Oncol
. 2024 Apr;
14:1378694.
PMID: 38571496
PRKCSH, also known as Glucosidase II beta subunit (GluIIβ), is a crucial component of the endoplasmic reticulum (ER) quality control system for N-linked glycosylation, essential for identifying and eliminating misfolded...
4.
Bekker A, Salvadori N, Rabie H, du Toit S, Than-In-At K, Groenewald M, et al.
Lancet HIV
. 2024 Jan;
11(2):e86-e95.
PMID: 38296364
Background: Existing solid antiretroviral fixed-dose combination formulations are preferred over liquid formulations in children, but their suitability for neonates is unknown. We evaluated the pharmacokinetics and safety of paediatric abacavir-lamivudine...
5.
Khaodee W, Xiyuan G, Han M, Tayapiwatana C, Chiampanichayakul S, Anuchapreeda S, et al.
BMC Genomics
. 2024 Jan;
25(1):82.
PMID: 38245670
Glucosidase II beta subunit (GluIIß), encoded from PRKCSH, is a subunit of the glucosidase II enzyme responsible for quality control of N-linked glycoprotein folding and suppression of GluIIß led to...
6.
Han M, Pornprasert S, Saeteng S, Tantraworasin A, Siwachat S, Thuropathum P, et al.
Asian Pac J Cancer Prev
. 2023 Oct;
24(10):3585-3598.
PMID: 37898867
Objective: This study aimed to assess the practicality and reliability of utilizing microRNAs (miRNAs) as a potential screening and diagnosing tool for non-small cell lung cancers (NSCLCs) in Northern Thailand....
7.
Niu X, Kubiak R, Siriprakaisil O, Klinbuyaem V, Sukrakanchana P, Cressey R, et al.
Open Forum Infect Dis
. 2022 Aug;
9(8):ofac405.
PMID: 36004315
Background: Tenofovir-diphosphate (TFV-DP) measured in dried blood spots (DBS) and tenofovir (TFV) measured in urine/plasma have been used to measure TFV-based oral pre-exposure prophylaxis (PrEP) adherence. However, there are limited...
8.
Liegeon G, Ngo-Giang-Huong N, Salvadori N, Bunpo P, Cressey R, Achalapong J, et al.
J Antimicrob Chemother
. 2022 Jan;
77(4):1111-1118.
PMID: 35045168
Background: Data evaluating the risk of proximal tubular dysfunction in women receiving tenofovir disoproxil fumarate for the prevention of mother-to-child transmission (PMTCT) of HBV are scarce. Objectives: To assess the...
9.
Bekker A, Rabie H, Salvadori N, du Toit S, Than-In-At K, Groenewald M, et al.
J Acquir Immune Defic Syndr
. 2021 Dec;
89(3):324-331.
PMID: 34855626
Background: Antiretroviral options for neonates (younger than 28 days) should be expanded. We evaluated the pharmacokinetics, safety, and acceptability of the "4-in-1" fixed-dose pediatric granule formulation of abacavir/lamivudine/lopinavir/ritonavir (30/15/40/10 mg)...
10.
Cressey T, Siriprakaisil O, Kubiak R, Klinbuayaem V, Sukrakanchana P, Quame-Amaglo J, et al.
Int J Infect Dis
. 2020 Jun;
97:365-370.
PMID: 32553717
Objectives: The aim was to fully characterize the plasma and urine washout pharmacokinetics of tenofovir (TFV) in adults following 6 weeks of controlled levels of tenofovir disoproxil fumarate (TDF) adherence,...